Integra Lifesciences Holdings Corp (IART) Stock
Key stats
- Market cap
- $1.15B
- Price / Earnings ratio
- 86.9x
- EPS (TTM)
- $0.17
- Volume
- Loading
- 52-week high
- $20.49
- 52-week low
- $8.70
Source: third-party data provider, as of November 13, 2026
Compare with IART
Recent news

Lost Money on Integra LifeSciences Holdings Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 21.2% Share Price Drop
Lost Money on Integra LifeSciences Holdings Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 21.2% Share Price Drop
IART

Did You Lose Money on Integra LifeSciences Holdings Corporation Stock? The Law Offices of Howard G.
Did You Lose Money on Integra LifeSciences Holdings Corporation Stock? The Law Offices of Howard G.
IART

Lost Money on Integra LifeSciences Holdings Corporation Shares? The Law Offices of Frank R.
Lost Money on Integra LifeSciences Holdings Corporation Shares? The Law Offices of Frank R.
IART

What Integra LifeSciences (IART) Said on Its Q3 Earnings Call
What Integra LifeSciences (IART) Said on Its Q3 Earnings Call
IART
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 57.57
- MACD 12/26/9
- 0.06
- EMA 9 of MACD
- -0.26
- MACD histogram
- 0.32
- SMA 50
- $14.41
- Price above SMA 50
- EMA 50
- $14.36
- Price above EMA 50
- SMA 200
- $14.15
- Price above SMA 200
- EMA 200
- $13.93
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.53 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Lost Money on Integra LifeSciences Holdings Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 21.2% Share Price Drop
Lost Money on Integra LifeSciences Holdings Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 21.2% Share Price Drop
IART

Did You Lose Money on Integra LifeSciences Holdings Corporation Stock? The Law Offices of Howard G.
Did You Lose Money on Integra LifeSciences Holdings Corporation Stock? The Law Offices of Howard G.
IART

Lost Money on Integra LifeSciences Holdings Corporation Shares? The Law Offices of Frank R.
Lost Money on Integra LifeSciences Holdings Corporation Shares? The Law Offices of Frank R.
IART

What Integra LifeSciences (IART) Said on Its Q3 Earnings Call
What Integra LifeSciences (IART) Said on Its Q3 Earnings Call
IART

Integra (IART) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Integra (IART) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
IART

Integra LifeSciences (IART) Surpasses Q3 Earnings Estimates
Integra LifeSciences (IART) Surpasses Q3 Earnings Estimates
IART

INTEGRA LIFESCIENCES HOLDINGS CORPORATION IART INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 21.2% Share Drop
INTEGRA LIFESCIENCES HOLDINGS CORPORATION IART INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 21.2% Share Drop
IART

Integra LifeSciences lowers revenue and earnings outlook for 2026
Integra LifeSciences lowers revenue and earnings outlook for 2026
IART

IART vs. PEN: Which Stock Is the Better Value Option?
IART vs. PEN: Which Stock Is the Better Value Option?
IART

Should You Continue to Hold IART Stock in Your Portfolio?
Should You Continue to Hold IART Stock in Your Portfolio?
IART
News tone: automated (AI) classification of the article's content, not a price prediction.
About Integra Lifesciences Holdings Corp
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Stuart M. Essig Ph.D. | CEO, President & Chairman | 1962 |
| Ms. Lea Daniels Knight | Executive VP & CFO | 1972 |
| Mr. Robert T. Davis Jr. | Executive Vice President of Tissue Reconstruction and Distributed Technologies | 1959 |
| Mr. Michael J. McBreen | Executive VP & Chief Commercial Officer | 1966 |
| Mr. Harvinder Pal Singh | Executive VP & President of International Business | 1966 |
| Mr. Jeffrey A. Mosebrook | Senior VP of Finance & Principal Accounting Officer | 1976 |
| Mr. Teshtar Elavia | Corporate VP & Chief Technology Officer | — |
| Christopher Ward | Senior Director of Investor Relations | — |
| Mr. Michael D. Hutchinson | Executive VP, Chief Legal Officer & Secretary | 1971 |
| Laurene Isip | Vice President of Global Corporate Communications & Public Relations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 57.57
- MACD 12/26/9
- 0.06
- EMA 9 of MACD
- -0.26
- MACD histogram
- 0.32
- SMA 50
- $14.41
- Price above SMA 50
- EMA 50
- $14.36
- Price above EMA 50
- SMA 200
- $14.15
- Price above SMA 200
- EMA 200
- $13.93
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $13.00
- Average
- $14.86
- High
- $22.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -6.5 | +7.2 | ||||||||||
| 2022 | -5.4 | +4.2 | -3.1 | -8.1 | +3.5 | -11.2 | +0.1 | -16.1 | -10.8 | +14.6 | +7.8 | -0.5 |
| 2023 | +2.9 | -5.0 | +4.7 | -2.7 | -31.8 | +7.1 | +10.9 | -5.4 | -10.7 | -5.4 | +6.4 | +6.2 |
| 2024 | -7.2 | -9.8 | -1.5 | -16.0 | +5.9 | -8.5 | -14.4 | -17.4 | -5.7 | +7.2 | +27.5 | -7.7 |
| 2025 | +13.4 | -10.7 | -2.2 | -24.2 | -23.0 | -0.4 | -0.8 | +22.9 | -5.5 | -18.5 | +14.2 | -4.9 |
| 2026 | -7.2 | +2.0 | -9.7 | +10.1 | +46.5 | +14.6 | -6.9 | -5.4 | -2.0 | -20.8 | +8.5 |



